- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07884448
PliaFX Flo Subtalar Fusion Study
A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada
During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.
This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Vroege fase 1
Contacten en locaties
Studiecontact
- Naam: Biraj Bora
- Telefoonnummer: 604-813-0889
- E-mail: biraj.bora@phc.ca
Studie Locaties
-
-
British Colombia
-
Vancouver, British Colombia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Contact:
- Biraj Bora
- Telefoonnummer: 604-813-0889
- E-mail: biraj.bora@phc.ca
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- The subject is at least 19 years of age.
- The subject is considered to be skeletally mature.
- The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
- The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
- The patient may undergo a subtalar fusion as part of a triple arthrodesis.
- The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
- The patient consented for either an arthroscopic or open procedure.
- The subject is able to comply with all post-operative evaluations and visits.
- The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery
Exclusion Criteria:
-
The subject has:
- Severe osteoporosis
- Neuromuscular impairment
- Prior infection in the affected joint
-
The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.
-
The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).
-
The subject is renal compromised.
-
The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).
-
The subject is undergoing a revision of a prior subtalar fusion.
-
The subject has had a prior ankle joint fusion.
-
An ankle joint replacement or ankle joint fusion may be performed during the same sitting.
-
The subject has a BMI of > 50 kg/m2.
-
The subject is known to be pregnant, or plans to become pregnant during the study period
-
The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).
-
The subject is unable to provide informed consent.
-
The subject is unable to communicate with the research team.
-
The subject is unable to comply with follow-up.
-
The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry
-
The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Toestel Haalbaarheid
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PliaFX Flo Allograft
Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure. |
Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure. |
|
Geen tussenkomst: No Graft
Participant will receive no graft during their Subtalar Arthrodesis procedure. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Bone Bridging Percentage
Tijdsspanne: Enrollment to last Follow-up visit (52 weeks)
|
Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively. |
Enrollment to last Follow-up visit (52 weeks)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Foot and Ankle Measure (FAAM) Questionnaire
Tijdsspanne: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Current Health Assessment Questionnaire
Tijdsspanne: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Tijdsspanne: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Demographics Questionnaire
Tijdsspanne: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
|
|
Ankle Osteoarthritis Scale
Tijdsspanne: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 1, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
SF-36 Health Survey
Tijdsspanne: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- H26-01617
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .